BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 23, 2007
 |  BioCentury  |  Strategy

Tweaking Canada's translational model

Canada's nascent effort to commercialize the nation's stem cell inventions via a centralized technology transfer company has added a business development component in the hopes of establishing proof of principle for its ability to bring Canadian technology to the marketplace.

In 1989, the Canadian government launched the Networks of Centres of Excellence (NCE) program to link scientific research with industrial experience and strategic investment.

In January 2006, one of the Centres - the Stem Cell Network (SCN) - went a step further and created a company to commercialize its technologies. Aggregate Therapeutics Inc. (Toronto, Ontario) has exclusive first right to negotiate the rights to commercialize unencumbered stem cell technologies from the...

Read the full 539 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >